Efficacy of switching to telbivudine in chronic hepatitis B patients treated previously with lamivudine.
Safadi
Rifaat
R
Hadassah Medical Center, Jerusalem, Israel. safadi@hadassah.org.il
Xie
Qing
Q
Chen
Yagang
Y
Yin
You-Kuan
YK
Wei
Lai
L
Hwang
Seong Gyu
SG
Zuckerman
Eli
E
Jia
Ji-Dong
JD
Lopez
Patricia
P
D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D015415:Biomarkers / Q000097:blood; D016009:Chi-Square Distribution; D004279:DNA, Viral / Q000097:blood; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D024882:Drug Resistance, Viral / Q000235:genetics; D057915:Drug Substitution; D005260:Female; D006513:Hepatitis B e Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000235:genetics / Q000276:immunology; D019694:Hepatitis B, Chronic / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D009705:Nucleosides / Q000008:administration & dosage* / Q000009:adverse effects; D011744:Pyrimidinones / Q000008:administration & dosage* / Q000009:adverse effects; D000077712:Telbivudine; D013936:Thymidine / Q000031:analogs & derivatives; D013997:Time Factors; D016896:Treatment Outcome; D019562:Viral Load; D014779:Virus Replication
D000998:Antiviral Agents; D015415:Biomarkers; D004279:DNA, Viral; D006513:Hepatitis B e Antigens; D009705:Nucleosides; D011744:Pyrimidinones; D000077712:Telbivudine; D019259:Lamivudine; D013936:Thymidine